<DOC>
	<DOCNO>NCT00102297</DOCNO>
	<brief_summary>The Phase 1b study multi-center trial design test safety , tolerability , biologic activity escalate dos FG-3019 20 patient type 1 type 2 diabetes microalbuminuria ( early-stage kidney disease ) . Patients receive either 3 10 mg/kg FG-3019 administer every two week infusion total four dos . The ability FG-3019 reduce excretion protein urine measure secondary endpoint .</brief_summary>
	<brief_title>Study Safety FG-3019 Incipient Nephropathy Due Type 1 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Written inform consent Body mass index exceed 32.0 kg/m2 If female , subject must meet one follow criterion : ) surgically sterile ( hysterectomy bilateral tubal ligation ) OR b ) least two year postmenopausal OR c ) use dual method contraception negative serum pregnancy test childbearing potential Diagnosis type 1 type 2 diabetes accord American Diabetes Association Fasting plasma glucose â‰¥ 126 mg/dL current treatment oral hypoglycemic agent insulin Microalbuminuria define albumin creatinine ratio spot collection ( first void ) 30 300 mg/gram confirm two sample two three day apart Serum creatinine 1.5 mg/dL men 1.1 mg/dL woman Female subject pregnant lactate Nondiabetic renal disease History allergic anaphylactic reaction human , humanize , chimeric , murine monoclonal antibody Coronary artery bypass graft surgery , myocardial infarction , cerebrovascular accident , percutaneous transluminal angioplasty , transient ischemic attack , history unstable angina , know heart failure , uncontrolled cardiac arrhythmia , uncontrolled hypertension within six month prior Day 0 Bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal History cancer type past 5 year , except non melanomatous skin cancer , localize bladder cancer , situ cervical cancer . Clinically significant uncontrolled medical condition consider high risk participation investigational study Trauma surgical procedure ( include dental ) within six month prior Day 0 Planned elective surgery study 3 month follow end study Participation study investigational drug within 6 week prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Incipient Nephropathy</keyword>
	<keyword>Type 1 Type 2 Diabetes</keyword>
</DOC>